The outcomes of radiotherapy in patients with ovarian carcinoma

Relapses of ovarian cancer have poor prognosis, overall survival (OS) after recurrence depends on patient's performance status, histological cell type, size and number of the relapse, and duration of the platinum-free interval. Pelvis, peritoneum, pleural effusion, liver, lung, lymph nodes, and central nervous system are the most frequent sites of relapse. The standard treatment for ovarian cancer is a combination of surgery and chemotherapy. This retrospective study aimed to describe incidence, characteristics, outcomes and prognostic factors of patients with ovarian cancer underwent radiotherapy. Results: In 47 with ovarian cancer underwent radiotherapy. Treatment modalities were radiotherapy 8- 56 Gy. After optimal treatment the authors observed complete remission in seven patients, and progression and/or metastases in 40 patients. The present study confirmed that patients with low advancement stage had better prognoses than patients with advanced disease, as confirmed by OS rates in groups T1 vs. T3 (p = 0.066) and T3 vs. T4 (p = 0.066). What was interesting was that the disease-free survival (DFS) in the group of patients with T3 cancer was longer than in the group of patients with T1 cancer. Time to marker progression (Ca 125) was longer in groups with FIGO Stage I vs. II and I vs. III (p = 0.016, p = 0.044), while the time to progression in FIGO Stage II cancer patients was shorter than in FIGO Stage III cancer patients. An interesting result was also obtained in the analysis of 36-month survival where a larger number of patients without the disease symptoms had T3 Stage cancer. New prospective studies, designed to include the aspects of target volumes, total doses and fraction doses, together with the use of state of the art planning techniques, and therapeutic instrumentation are required.

Cancer; Ovary; Radiotherapy; Brachytherapy.

[1] Reinfuss M., Czepko A., Lesiak J., Kojs Z.: “Napromienianie chorych na raka jajnika technika “wędrujących pasków”. Wstępna ocena tolerancji i skuteczności”. Nowotwory, 1989, 39, 53. [Article in Polish]

[2] Urban A., Miszczyk L.:” Rak jajnika- diagnostyczny i terapeutyczny problem ginekologii onkologicznej”. Cotenporary Oncol., 2003, 7, 294. [Article in Polish]

[3] Teckie S., Makker V., Tabar V., Alektiar K., Aghajanian C., Hensley M., Beal K.: “Radiation therapy for epithelial ovarian cancer brain metastases:clinical outcomes and predictors of survival”. Radiat. Oncol., 2013, 8, 36.

[4] Zieliński J., Krzakowski M.: “Onkologia Kliniczna tom II”. 1sted. Krzakowski M. (ed). Warsaw: Borgis, 2001, 141.

[5] Nagai Y., Inamine M., Hirakawa M., Kamiyama K., Ogawa K., Toita T., et al.: “Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary.” Gynecol. Oncol., 2007, 107, 469.

[6] Dembo A.: “Abdominopelvic radiotherapy in ovarian cancer. A 10- year experience”. Cancer, 1985, 55, 2285.

[7] Goldhirsch A., Greiner R., Dreher E., Sessa C., Krauer F., Forni M., et al.: “Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy”. Cancer, 1988, 62, 40.

[8] Buser M., Bacchi A., Goldhirsch R., Greiner R., Diener P., Sessa C., et al.:” Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation”. Ann. Oncol., 1996, 7, 65.

[9] Wong R., Milosevic M., Sturgeon J., Pintilie M., Fyles A., Levin W.: “Treatment of early epithelial ovarian cancer with chemotherapy and abdominopelvic radiotherapy: results of a prospective treatment protocol”. Int. J. Radiat. Oncol. Biol. Phys., 1999, 45, 657.

[10] Hacker N., Berek J., Burnison C., Heintz P., Juillard G., Lagasse L.: “Whole abdominal radiation as salvage therapy for epithelial ovarian cancer”. Obstet. Gynecol., 1985, 65, 60.

[11] Fyles A.W., Dembo A.J., Bush R.S., Levin W., Manchul L.A., Pringle J.F., et al.: “Analysis of complications in patients treated with abdomino- pelvic radiation therapy for ovarian carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 1992, 22, 847.

[12] Gelblum D., Mychalczak B., Almadrones L., Spriggs D., Barakat R.: “Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma.” Gynecol. Oncol., 1998, 69, 36.

[13] Blanchard P., Plantade A., Pages C., Afchain P., Louvet C., Tournigand C., de Gramont A.: “Isolated lymph node relapse of epithelial ovarian carcinoma: Outcomes and prognostic factors”. Gynecol. Oncol., 2007, 104, 41.

[14] Pereira A., Perez-Medina T., Magrina J., Magtibay P.M., Millan I., Iglesias E.: “The role of lyphadenectomy in node-positive epithelial ovarian cancer”. Int. J. Gynecol. Cancer, 2012, 6, 22.

[15] Corn B., Greven K., Randal M., Wolfson A., Kim R., Lanciano R.: “The efficacy of cranial irradiation in ovarian cancer metastatic to the brain: analysis of 32 cases”. Obstet. Gynecol., 1995, 86, 955.

[16] Tinger A., Waldron T., Peluso N., Katin M.J., Dosoretz D., Blitzer P., et al.:” Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 2001, 51, 1256.

[17] Sorbe B.: “Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment”. Int. J. Gynecol. Cancer, 2003, 13, 278.

[18] Petit T.,Velten M., d'Hombres A., Marchal C., Montbarbon X., Mornex F., et al.:” Long term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy”. Gynecol. Oncol., 2007, 104, 104.

[19] Dowdy S., Metzinger D., Gebhart J., Srivatsa P., haddock M., Suman V.: “Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer”. Gynecol. Oncol., 2005, 96, 389.

[20] Fujiwara K., Suzuki S., Yoden E., Ishikawa H., Imajo Y., Kohno I.: “Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemiotherapy”. Int. J. Gynecol. Cancer, 2002, 12, 250.

[21] Delaney G., Jacob S., Barton M.: “Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma”. Cancer, 2004, 101, 671.

[22] Biedka M., Żmuda E.: “Możliwe zastosowanie radioterapii u pacjentek z rakiem jajnika”. Oncol. Radiotherapy, 2013, 3, 18.

[23] Murakami N., Kasamatsu T., Sumi M., Yoshimura R., Harada K., Kitaguchi M., et al.: “Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies”. Radiat. Oncol., 2014, 9, 31.

[24] Rochet N., Jensen A., Sterzing F., Munter M.W., Eichbaum M.H., Schneeweiss A., et al.: “Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01)-pilot trial of phase I/II study”. BMC Cancer, 2007, 7, 227.

[25] Rochet N., Kieser M., Sterzing F., Krause S., Lindel K., Harms W., et al.:” Phase II study evaluating consolidation whole abdominal intensity- modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III-The OVAR-IMRT-02 Study”. BMC Cancer, 2011, 11, 41.

[26] Mahantshetty U., Jamema A., Engineer R., Deshpande D., Sarin R., Fogliata A., et al.: “Whole abdomen radiation therapy in ovarian cancers: a comparison between fixed beam and volumetric arc based intensity modulation”. Radiat. Oncol., 2010, 5, 106.

[27] Shetty U., Shankar S., Engineer R., Chopra S., Gupta S., Maheshwari A., et al.: “Image-guided intensity-modulated whole-abdominal radiation therapy in relapsed epithelialovarian cancers: A feasibility study”. J. Can. Res. Ther., 2013, 9, 17.

[28] Biedka M., Śpiewankiewicz B.: “Zastosowanie radioterapii śródoperacyjnej w nowotworach wywodzących się z narządów płciowych kobiet”. Curr. Gyncol. Oncol., 2012, 3, 215.